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Phenytoin (PHT) is a first-line drug in the treatment of status epilepticus. However, the parenteral PHT formulation is associated
with administration difficulties and therefore fosphenytoin (FosPHT), a PHT pro-drug, has been developed. As the peripheral
(blood) and central (cerebrospinal fluid [CSF] and brain extracellular fluid [ECF]) kinetic inter-relationship of PHT after i.v.
FosPHT administration is unknown we sought to ascertain the relationship and to compare it to that of i.v. PHT. A freely
behaving rat model, which allows for the concurrent and temporal sampling of blood (jugular vein), CSF (cisterna magna) and
brain ECF (frontal cortex and hippocampus), was used. PHT and FosPHT were administered by i.v. infusion and blood, CSF and
microdialysate samples collected at timed intervals up to 6 hours. The pharmacokinetic parameters in plasma of PHT after PHT
and FosPHT (30 and 60 mg/kg) administration were indistinguishable. The PHT plasma free fraction (free/total concentration
ratio) was 0.25–0.31 and 0.26–0.31 for PHT and FosPHT, respectively. Mean PHT Tmax values for CSF were 9–13 minutes. The
equivalent values in the frontal cortex and hippocampal ECF were 29–34 minutes. Cmax values increased dose-dependently and
were independent of whether PHT or FosPHT was administered. Furthermore the kinetic profiles of PHT for the frontal cortex
and hippocampus were indistinguishable suggesting that PHT distribution in the brain is not brain region specific. Thus, overall,
the central and peripheral kinetics of PHT are indistinguishable after PHT and FosPHT.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Phenytoin (PHT, Epanutin, Dilantin, Pfizer Ltd) is a
first-line drug in the treatment of convulsive status
epilepticus1. Although after intravenous or intramus-
cular administration, PHT enters the central nervous
system rapidly so that seizure control is prompt and
effective, it has numerous undesirable characteris-
tics. Because PHT is poorly soluble, formulation for
parental use requires the use of a vehicle of 40%
propylene glycol and 10% alcohol adjusted to a pH of
12 with sodium hydroxide. Intravenous administration
of this formulation can result in hypotension, cardiac
dysrhythmias and decreased pulse rate2, 3, which has
been attributed to the propylene glycol vehicle3, 4.
Consequently, its administration has to be slow so as to
avoid these complications5, 6. In addition, extravasa-
tion tends to cause local soft tissue and vein injury7, 8.
In order to overcome these problematic charac-
teristics, fosphenytoin (FosPHT; a disodium salt of
5,5-diphenyl-3-[(phosphonooxy)methyl]-2-4-imidazo-
lidinedione), a phenytoin pro-drug, has been devel-
oped (Cerebyx, Pfizer Ltd). Because FosPHT is water
soluble, allowing formulation with a more physio-
logically compatible vehicle, it exhibits a number of
advantages over PHT. It has better intravenous fluid
compatibility and stability and therefore causes far
less cardiovascular, hepatic and renal adverse effects
and can be administered at a faster rate. Furthermore,
because FosPHT does not have a high pH value, it
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is associated with far less pain and burning at the
infusion site and indeed minimal consequences occur
after intravenous infiltration. These characteristics al-
low for a longer maintenance of intravenous infusion
site9. FosPHT is also well tolerated when adminis-
tered intramuscularly10, 11.
Because of the extensive use of PHT in the man-
agement of epilepsy in general and its use specifically
in status epilepticus, along with the fact that it has
some unique and peculiar pharmacokinetic charac-
teristics, the central (cerebrospinal fluid [CSF] and
extracellular fluid [ECF]) and peripheral (blood) ki-
netic inter-relationship of PHT has been extensively
studied in both man and in animals12–16. In contrast,
kinetic studies of FosPHT have been confined to
the blood compartment, primarily in man, although
one animal study reported on its blood kinetics after
i.p. administration17 whilst two other studies reported
on its blood and whole brain kinetics after i.p.18 and
i.v. administration19. The latter study reported that
initial whole brain PHT concentrations were lower
after FosPHT administration compared to that after
equal molar PHT administration and therefore it was
suggested that the efficacy of FosPHT might be less
compared to that of PHT. However, whole brain drug
concentrations do not necessarily reflect drug content
at the site of drug action. Therefore, in the present
study we investigated the kinetic inter-relationship of
PHT in blood (plasma), CSF and brain ECF (frontal
cortex and hippocampus) after intravenous adminis-
tration of PHT and FosPHT in the freely behaving rat.
METHODS
Animals
Male Sprague–Dawley rats weighing 310–390 g (A.
Tuck & Son Ltd, Battlesbridge, Essex, UK) were
group housed in contiguous cages and fed ad libitum
on normal laboratory diet (SDS R and M number
1 expanded, Scientific Dietary Services, Witham,
Essex, UK) and water. A 12-hour light:12-hour dark
cycle (lights on 06:00 hour) and ambient temperature
of 25 ◦C were maintained. All animal procedures
strictly followed Home Office regulations and were
performed under the Animal (Scientific Procedures)
Act 1986.
Surgical procedures, blood, CSF and
microdialysis sampling
Rats were anaesthetised with 2% halothane (Merial
Animal Health Ltd, Dublin, Ireland) inhalation. Two
surgical procedures were undertaken. In the first,
catheters were implanted in the cisterna magna for
CSF sampling, and the right jugular vein for blood
sampling as previously described20. The second pro-
cedure involved the implantation of microdialysis
probes in both the hippocampus (from bregma 5.6 mm
posterior, 5 mm lateral, 8.2 mm ventral) and the frontal
cortex (from bregma 2.5 mm anterior, 1.5 mm lateral,
5.5 mm ventral) according to the atlas of Paxinos and
Watson21. In addition, a catheter was implanted in
the right internal jugular vein for blood sampling22.
Animals with blood and CSF catheters were investi-
gated as follows: FosPHT (30 or 60 mg/kg PHT equiv-
alents [PEs]; 200µl/minute) or PHT (30 or 60 mg/kg;
100µl/minute) were administered by intravenous in-
fusion (infusion took 4 minutes for PHT and half the
time for FosPHT). Blood (200µl) and CSF (20µl)
were sampled via implanted catheters at timed inter-
vals over a 6-hour period (5, 15, 30, 45, 60, 90, 120,
150, 180, 240, 300 and 360 minutes). Blood samples
were collected in 0.5 ml polyethylene tubes (Treff AG,
Switzerland) containing 10µl of 0.55 M EDTA pH
14 (dissolved in 3 M sodium hydroxide). The EDTA
served to prevent the in vitro conversion of FosPHT to
PHT19. Plasma and CSF were stored frozen (−70 ◦C)
until analysis for PHT content.
Animals with blood catheters and microdialysis
probes were investigated as follows: artificial CSF
(CSF composition in mM: NaCl 125, KCl 2.5, MgCl2
1.18 and CaCl2 1.26) was perfused through the probes
at 2µl/minute. Dialysate samples (20µl) were col-
lected at 10-minute intervals for the first 60 minutes,
at 15-minute intervals for the subsequent 60-minute
period and thereafter at 30-minute intervals for a
further 240 minutes. Blood sampling was undertaken
and the samples processed as described above.
Microdialysis probe construction and
in vitro recovery
Concentric microdialysis probes were prepared as pre-
viously described23. In vitro probe recovery was de-
termined by placing each microdialysis probe into a
beaker containing 24µM solution of PHT dissolved
in artificial CSF and then perfused with artificial CSF
at 2µl/minute. Samples (40µl) were collected every
20 minutes for 100 minutes and stored at −70 ◦C until
analysis for PHT content.
Measurement of PHT concentration
Plasma (50µl), CSF (20µl) or microdialysate (20µl)
were analysed for PHT content by high performance
liquid chromatography24. The limit of quantifica-
tion for PHT was 0.5µmol/l (CV, 10.1%) and the
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extraction recovery for plasma, CSF and dialysate was
92–103%. The procedure used for the determination
of the free non-protein-bound plasma PHT concen-
trations was the same as for total PHT concentrations
except that samples were first filtered through an
Amicon Centrifree Micropartition System (Amicon,
Stonehouse, UK) using a Sigma 2K15 centrifuge set
at 25 ◦C.
Kinetic and statistical analysis
PHT versus time data for blood were analysed ac-
cording to a two-compartment model, whereby for
CSF and microdialysate a one-compartment model
was used. The parameters computed were as follows:
area under the concentration versus time curve (AUC)
and apparent elimination half-life (t1/2). Time to max-
imum concentration (Tmax) and maximum concentra-
tion (Cmax) were obtained by direct inspection of the
PHT concentration versus time profiles. Pharmacoki-
netic constants were compared by the Mann–Whitney
test and a P-value <0.05 was considered to be statis-
tically significant.
RESULTS
Blood pharmacokinetics
The mean (±SEM) pharmacokinetic constants for
PHT after PHT and FosPHT administration are shown
in Table 1. Peak plasma PHT concentrations were
Table 1: Pharmacokinetic constants of PHT in blood, CSF and brain ECF after intravenous administration of PHT and FosPHT
(dosage of FosPHT is equivalent of PHT).
Mean (±SEM)
Tmax (minute) Cmax (µmol/l) AUC (µmol hour/l) t1/2 (minute)
Plasma
PHT (30 mg/kg) – 157 ± 19 112 ± 10 46 ± 6
FosPHT (30 mg/kg) – 175 ± 11 139 ± 17 47 ± 6
PHT (60 mg/kg) – 338 ± 26 536 ± 86 130 ± 16
FosPHT (60 mg/kg) – 343 ± 18 668 ± 46 131 ± 4
CSF
PHT (30 mg/kg) 9 ± 1 15 ± 2 23 ± 4 57 ± 9
FosPHT (30 mg/kg) 12 ± 2 14 ± 1 20 ± 2 56 ± 6
PHT (60 mg/kg) 13 ± 4 34 ± 5 105 ± 14 157 ± 25
FosPHT (60 mg/kg) 10 ± 1 33 ± 4 78 ± 6 111 ± 11
Frontal cortex ECF
PHT (60 mg/kg) 34 ± 2 10 ± 1 47 ± 11 244 ± 50
FosPHT (60 mg/kg) 29 ± 4 10 ± 1 67 ± 19 266 ± 64
Hippocampal ECF
PHT (60 mg/kg) 32 ± 4 10 ± 1 45 ± 8 234 ± 39
FosPHT (60 mg/kg) 34 ± 3 9 ± 1 41 ± 10 222 ± 70
n = 5–8; Tmax: time to maximum concentration; Cmax: maximum concentration; AUC: area under the concentration versus time curve;
t1/2: terminal elimination half-life.
achieved by the end of intravenous infusion of both
PHT and FosPHT. During the subsequent 15 minutes,
concentrations rapidly declined, and the decline con-
tinued in an exponential manner (Fig. 1a). The distri-
bution (alpha-phase) t1/2 values were of the order of
10 minutes and were neither drug nor dose-dependent.
PHT Cmax values increased dose-dependently after
administration of both PHT and FosPHT. However,
AUC and t1/2 values increased disproportionately to
dose. Thus, doubling the dose of both PHT and Fos-
PHT was associated in a threefold increase in terminal
t1/2 values. Overall, the pharmacokinetic parameters
for PHT after PHT and FosPHT administration were
indistinguishable.
The free non-protein-bound PHT concentration was
determined in plasma during 5–60 minutes after PHT
and FosPHT administration. After PHT administra-
tion, the free fraction was 0.25–0.31, whilst after Fos-
PHT administration it was 0.26–0.31. Values were
not dependent on drug formulation administration and
were neither dose nor time-dependent.
Neuropharmacokinetics
CSF
The mean (±SEM) neuropharmacokinetic constants
for PHT in CSF after PHT and FosPHT administra-
tion are shown in Table 1. PHT was rapidly detectable
in CSF after PHT and FosPHT administration. Mean
Tmax values varied between 9 and 13 minutes and
were neither dose- nor formulation-dependent. After
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Fig. 1: Plasma PHT (a) and cerebrospinal fluid (b) PHT concentration versus time profiles after intravenous administration of
PHT and FosPHT at 30 mg/kg and 60 mg/kg. (Dosage of FosPHT is equivalent of PHT.) Values are mean± SEM; n = 5–7.
administration of PHT and FosPHT, Cmax values in-
creased dose-dependently and subsequently PHT con-
centration declined exponentially (Fig. 1b). However,
although AUC and t1/2 values increased disproportion-
ately to dose after PHT administration, as observed in
plasma, values increased dose-dependently after Fos-
PHT administration. Overall, the pharmacokinetic pa-
rameters in CSF were indistinguishable after FosPHT
and PHT administration.
By 15 minutes post PHT and FosPHT administra-
tion there was a tendency towards equilibration (as
measured by a constant CSF/plasma PHT concentra-
tion ratio) between the blood and CSF compartments
after the administration of both 30 and 60 mg/kg PHT
and FosPHT. For PHT administration the CSF/plasma
ratio (mean± SEM) was 0.12± 0.005 whilst for Fos-
PHT administration it was 0.19 ± 0.013 (P < 0.01,
Mann–Whitney test).
Extracellular fluid
The in vitro relative recovery of PHT for all the mi-
crodialysis probes was 18 ± 2% (mean ± SEM) at a
dialysate flow rate of 2µl/minute. These data were
used to adjust the in vivo ECF concentration data.
The mean (±SEM) PHT neuropharmacokinetics
constants in rat brain frontal cortex and hippocampal
ECF are shown in Table 1. The corresponding PHT
concentration versus time profiles are shown in Fig. 2.
PHT was detectable at time of first dialysate sample
(10 minutes) for both PHT and FosPHT administra-
tion. However, peak PHT concentrations were not
achieved until after half an hour, then decreased ex-
ponentially. AUC and t1/2 values in frontal cortex
were comparable to that in hippocampus and indeed
there was no significant difference in these values
when PHT and FosPHT administration are compared.
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Fig. 2: Extracellular fluid PHT concentration versus time profiles in frontal cortex (a) and in hippocampus (b) after intravenous
administration of PHT and FosPHT at 60 mg/kg. (Dosage of FosPHT is equivalent of PHT.) Values are mean± SEM; n = 6–8.
However, ECF t1/2 values were two-fold greater than
those observed in blood and CSF.
The ECF/plasma PHT concentration ratio was in-
distinguishable during the first 30 minutes in both
frontal cortex and hippocampus for PHT and FosPHT
(60 mg/kg). Subsequently, however, the ratio was
higher after FosPHT administration (0.065± 0.008 in
frontal cortex vs. 0.06± 0.007 in hippocampus) com-
pared to that after PHT administration (0.054± 0.006
in frontal cortex vs. 0.053 ± 0.005 in hippocampus;
P < 0.05, Mann–Whitney test).
DISCUSSION
A rapid and effective therapeutic response is essen-
tial in the management of status epilepticus and Fos-
PHT has been developed as a PHT pro-drug in this
regard. However, an important consideration relates
to how the penetration of PHT, derived from Fos-
PHT, into the brain site of action compares to that of
PHT after the administration of the parenteral formu-
lation, particularly since a recent report has suggested
that PHT whole brain tissue concentrations are sig-
nificantly lower after i.v. FosPHT compared to PHT
administration19. Therefore, this study was designed
to compare the kinetics of PHT in plasma, CSF and
brain (frontal cortex and hippocampus) ECF after i.v.
administration of PHT and FosPHT. This was achieved
by use of a well-validated freely behaving rat model23,
which uniquely allows concurrent blood and CSF sam-
pling and ECF monitoring.
The pharmacokinetics of PHT in plasma after i.v.
PHT and FosPHT are indistinguishable (Table 1) and
indeed the concentrations versus time profiles are es-
sentially super-imposable (Fig. 1a). Furthermore, the
classical well-characterised dose-dependent saturation
kinetics of PHT was seen after both PHT and Fos-
PHT administration, with comparable increases in t1/2
values13, 25–27 (Table 1).
As in the case of the blood compartment, the ki-
netics of PHT after PHT and FosPHT in the CSF
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compartment was indistinguishable. Rapid PHT
CSF penetration was observed after the adminis-
tration of both PHT and FosPHT with Tmax val-
ues of 9–13 minutes (Fig. 1b). Furthermore, PHT
equilibration between the blood and CSF compart-
ments occurred within 15 minutes of administration
of both PHT and FosPHT. The dose-dependent in-
crease in CSF concentrations suggests that transport
across the blood–brain barrier is not rate limit-
ing over the concentration range observed in this
study.
Since some drugs, including PHT, have been re-
ported not to be uniformly distributed within the
brain12, 28, microdialysis monitoring of ECF in spe-
cific brain sites has been used as an appropriate index
of drug distribution at putative sites of drug action.
In the present study we monitored ECF of the frontal
cortex and hippocampal. After PHT or FosPHT ad-
ministration PHT rapidly appeared in the brain as
evidenced by the fact that PHT was detectable in the
ECF of both brain regions at time of first sample
(10 minutes; Fig. 2). Furthermore, not only was there
no difference in the kinetic profiles of PHT after PHT
and FosPHT administration but also, in addition,
there were no brain regional differences as kinetic pa-
rameters in the frontal cortex and hippocampus were
indistinguishable (Table 1). It might be expected that
Tmax values in ECF would be shorter than that for CSF
but in fact they were longer and indeed this has been
observed in a recent study of the antiepileptic drug
levetiracetam24. The observed difference in Tmax value
is probably, in part, a reflection of methodology in that
CSF was directly sampled (and reflects point analysis)
whereas ECF was not (and reflects period analysis).
Also, the difference may be a consequence of the fact
that the blood–CSF barrier via the choroid plexus is
different to that of the blood–brain barrier associated
with ECF.
Previously, using rat whole brain homogenates,
Walton et al.19 reported that PHT concentrations
were significantly greater after i.v. PHT administra-
tion compared to i.v. FosPHT administration. Those
data are in contrast to the present study where PHT
brain (frontal cortex and hippocampal) ECF concen-
trations were indistinguishable after i.v. PHT and
FosPHT administration and emphasises the need to
be cautious about whole brain drug data which may
not necessarily reflect the pharmacologically relevant
drug compartment.
In conclusion, therefore, this study has shown that, at
least in the rat, there is no significant difference in the
kinetics of PHT in blood, CSF and ECF compartments
of the brain frontal cortex and hippocampus when i.v.
PHT and i.v. FosPHT are compared. Thus FosPHT
can be expected to be pharmacodynamically identical
to that of parenteral PHT and indeed at equimolar
doses in experimental seizure models, this is in fact
the case17, 29.
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